Richard D. Klausner
Founder & Executive ChairmanDr. Richard D. Klausner, also known as Rick, MD, is Scientific advisor & director of Orca Biosystems Inc. He is Member of Healthcare Advisory Board at Hippocratic AI, Inc. from November 2024. Dr. Klausner has been a Director at Fog Pharmaceuticals, Inc. since November 2022. He is Independent Non-Employee Director of Parabilis Medicines since November 2022. He serves as Director of Ohalo Genetics. He is the President of the Milky Way Research Foundation and founder and Managing Partner of Milky Way Investments. He is co-founder and director of Prometheus and director of Catharos. He is the Founder, Co-Chairman and Chief Scientific Advisor at Altos Labs, Inc. He serves as a Director at Medical Creations, Inc. He served as Director at Bit Bio Limited since 2025 until February 2026. He was a Co-Founder and Executive Chairman of Mindstrong, Inc. until December 2021. He is the Founder of Lyell Immunopharma, Incorporated. and serves as its Executive Chairman since 2020 and serves as its director from September 2018. He was the Chief Executive Officer of Lyell Immunopharma, Inc. from September 2018 to July 2020. He serves as the Chief Strategy Advisor for USAID. He served as the Chairman of Sonoma Biotherapeutics, Inc. until March 2026 and had been its Director since September 30, 2020 until July 2026. He serves as Scientific Advisor of Cyterix Pharmaceuticals Inc. He served in multiple senior leadership positions at Illumina Corporation, including as Senior Vice President, Chief Medical Officer and Chief Opportunity Officer from September 2013 to February 2016. He is a Co-Founder and Chairman of Lifemine Therapeutics and Director of Xtremity Prosthetics. He served as the Chief Medical Officer and Senior Vice President of Illumina Inc. from September 23, 2013 to March 31, 2016 and served as its Interim General Manager of Oncology since 2013 and served as Chief Opportunity Officer. He was responsible for Illumina's strategies for advancing genomics into clinical medicine and public health. He is also part of Illumina's executive management team, which is responsible for directing all aspects of company strategy, planning and operations. He co-founded Pathwork Diagnostics, Inc. and Juno Therapeutics Inc. in 2002. He is a Director of Juno Therapeutics. He served as the Managing Partner at Column Group Venture Partners I, L.P and The Column Group LLC. He worked at NIADDK from 1981 to 1984, when he served as Chief of the Cell Biology and Metabolism Branch at National Institute of Child Health and Human Development. He serves as Chair of LifeMine, Medical Creations and Wisdo. He also serves as Executive Chairman of Mindstrong Health. He served as Chairman of Rally Health, Inc. He served as the Chairman and Member of the Strategic Development and Scientific Advisory Council at Sanofi from March 1, 2011 to January 2013. He served as Co-Chairman of the Scientific Advisory Board and Scientific Advisor at Aragon Pharmaceuticals, Inc. He is an Executive Chairman of Wisdo. He serves as a Member of Scientific Advisory Board and Member of the Board of Directors at Rally Health, Inc. He was a Director of Juno Therapeutics Inc. from August 2013 to March 6, 2018. He served as a Director of GRAIL, Inc. January 2016 and served as its Member of Scientific Advisory Board. He served as Member of Scientific Advisory Board at Immune Design Corp. He served as Member of Scientific Advisory Board at Constellation Pharmaceuticals Inc. He served as a Member of Scientific Advisory Board at Infinity Pharmaceuticals, Inc., NGM Biopharmaceuticals, Inc., Aveo Pharmaceuticals, Inc., Igenica, Inc. and T2 Biosystems, Inc. He Chairs the Grand Challenges in Cancer program of Cancer Research UK. He served as a Director of Pathwork Diagnostics, Inc. and Immune Design Corp. He served as a Director of 3-V Biosciences, Inc. He served as a Director of National Cancer Institute from August 1, 1995 to 2001. He was Executive Chairman of Audax Health. He served as a Distinguished Scientific and Strategic Advisor of Aveo Pharmaceuticals, Inc. He served as a Director of Infinity Pharmaceuticals, Inc. He serves as the Chairman of the National Science Education Standards Projects of the National Academy of Science and oversees the first comprehensive process to provide a vision of scientific literacy in the American educational system and the criteria required to achieve it. He has been a Member of the National Academy of Sciences since 1993 and the American Academy of Arts and Sciences since 1995. He is also a Member of the Institute of Medicine. He worked on the Editorial Boards of several scientific journals, including Chemistry and Biology, Analytical Chemistry, New Biologist, Cell, the Annual Review of Cell Biology and the Journal of Cell Biology. He served as a Senior Fellow at the National Academies of Science. At NCI, he, along with Dr. Anthony Fauci, oversaw the creation and development of the Vaccine Research Center. He served as an Executive Director for Global Health at the Bill & Melinda Gates Foundation since 2002 until 2005. He served as the President at the American Society of Clinical Investigation. He served as an Advisor to the President of the Academies for counterterrorism and a Liaison to the White House Office of Science and Technology Policy. From 1979 to 1981, he worked at NIH in National Cancer Institute's (NCI) Laboratory of Mathematical Biology. Dr. Klausner was appointed by President Clinton and Bush as the eleventh Director of the U. S. National Cancer Institute between 1995 and 2001. He was one of the cited scientists in the world in cellular and molecular biology, his research was recognized with numerous awards and honors, including the Outstanding Investigator Award from the American Federation of Clinical Research and the William Damashek Prize for major discoveries in hematology. He received the 1997 and 1998 Dickson Prize in Medicine and the 1998 Raymond Bourgine Award. Dr. Klausner is the Author of a textbook of medical immunology and of a widely used textbook of internal medicine. Dr. Klausner received honorary degrees from Duke University, Queens University, Ohio State University, Mt. Sinai College of Medicine and Ben Gurion University. Dr. Klausner trained in internal medicine at Massachusetts General Hospital and was a Fellow in Internal Medicine at Duke Medical Center in 1976 to 1977. He has post-graduate medical training at Harvard. Dr. Klausner received an M.D. from Duke University School of Medicine and a BS in Molecular Biophysics and Biochemistry from Yale University.
Positions
- Company NameLyell Immunopharma, Inc.Stock CodeLYELPositionFounder & Executive ChairmanColleagues
- LSLynn SeelyPrincipal Executive Officer, President, CEO & Director
- SJStephen J. HillChief Operating Officer
- GKGary K. LeeChief Scientific Officer
- SRStanley R. RiddellFounder & Scientific Advisor
- CJCatherine J. FriedmanLead Independent Director
- WJWilliam JL RieflinIndependent Director
- OWOtis Webb BrawleyIndependent Director
